Bris­tol My­ers deep­ens ADC pipeline in $1B+ biobuck pact with Mu­nich start­up

Most of the an­ti­body-drug con­ju­gate talk late­ly has been cen­tered around Pfiz­er’s $43 bil­lion deal with Seagen, but Bris­tol My­ers Squibb is look­ing to up its game in the field by ink­ing a mod­est up­front for work out of a Ger­man biotech.

The Big Phar­ma will pay $22.75 mil­lion to Mu­nich-based Tubu­lis to snag ex­clu­sive rights to the start­up’s plat­form to make AD­Cs for sol­id tu­mors. BMS will choose an­ti­body tar­gets and Tubu­lis will then hand over link­er-pay­loads from its plat­form to cre­ate a match­ing ADC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER